Adynovate FDA Approval History
FDA Approved: Yes (First approved November 13, 2015)
Brand name: Adynovate
Generic name: antihemophilic factor (recombinant) pegylated
Company: Baxalta Incorporated
Treatment for: Hemophilia A
Adynovate (antihemophilic factor (recombinant) pegylated) is a human antihemophilic factor indicated for the control and prevention of bleeding episodes in patients with hemophilia A.
Development timeline for Adynovate
| Date | Article |
|---|---|
| Dec 27, 2016 | Approval Shire Announces FDA Approval of Adynovate [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical Settings |
| Nov 13, 2015 | Approval FDA Approves Adynovate Modified Antihemophilic Factor for Hemophilia A |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
